NCT02435927View on ClinicalTrials.gov

ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin

PHASE1UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Solid Tumors
Interventions
DRUG

ASLAN001+ CAPOX (Oxaliplatin, capecitabine)

ASLAN001 in combination with oxaliplatin and capecitabine

DRUG

ASLAN001 + mFolfox6 (5-FU, leucovorin)

ASLAN001 in combination with 5-FU and leucovorin

Trial Locations (1)

169610

National Cancer Centre, Singapore

Sponsors

Collaborators (1)

ASLAN Pharmaceuticals
All Listed Sponsors
collaborator

ASLAN Pharmaceuticals

OTHER

collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

lead

National Cancer Centre, Singapore

OTHER